Cupid announced a 4:1 bonus issue alongside stellar Q3 results, with profit surging 196% and income doubling. Record EBITDA margins, strong export demand and FMCG growth marked its strongest-ever quarter, reflecting confidence in long-term expansion and wider retail participation.
Canara Bank posted a 26% rise in Q3 net profit to Rs 5,155 crore, supported by 14% advance growth, higher operating income, and improving asset quality, with gross and net NPAs declining significantly year-on-year.
Indian markets rose for a third day, led by financials and energy. Hindustan Copper hit a record, L&T and Vedanta gained, eClerx jumped on results, while BEL slipped on brokerage views and Five-Star fell after earnings pressure elsewhere persisted modestly.
Staffing and workforce solutions provider Quess Corp reported a 32 per cent year-on-year rise in consolidated net profit to Rs 55.09 crore for the quarter ended December 31, 2025.
Dabur India posted a 7% rise in Q3 profit and 6% revenue growth, led by FMCG expansion, strong India market share gains and double-digit international growth. Sequential profits jumped sharply, underscoring resilient demand, brand strength and broad-based category performance.
Aswath Damodaran argues 2025 market moves reflect a deep trust deficit in US institutions. Bonds stayed calm, the dollar weakened, gold and silver surged, while bitcoin failed to act as a haven, trading like a risky equity throughout the year.
Indian Energy Exchange posted an 11% YoY rise in consolidated Q3 profit to Rs 119 crore, driven by stronger revenue and higher trading volumes. The company declared a Rs 1.50 interim dividend. Revenue grew 14% YoY to Rs 183 crore, while power prices softened and IGX reported steady growth in gas-trading volumes.
Hindustan Zinc’s OFS drew strong interest, with the retail portion subscribed 2.3 times on Day 2 as investors bid for 1.10 crore shares against 47.58 lakh on offer. This followed a robust 142% non-retail subscription on Day 1, underscoring solid demand at the Rs 685 floor price despite the stock trading higher.
Piramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and regulatory delays. Management sees recovery signs, cost controls cushioning EBITDA, and expects a stronger Q4.
The Indian rupee hit a record low against the dollar on Thursday, pressured by dollar demand linked to the maturity of non-deliverable forward positions and corporate hedging, while the central bank likely intervened to hold it above the psychologically significant 92 level.
Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.